Suppr超能文献

由Friend病毒诱导的白血病的肿瘤相关抗原所提供的体外细胞免疫反应性和肿瘤排斥反应。

Cellular immune reactivity in vitro and tumor rejection provided by tumor-associated antigens of friend-virus-induced leukemia.

作者信息

Dean J H, McCoy J L, Law L W, Maurer B A, Appella E

出版信息

Int J Cancer. 1975 Nov 15;16(5):701-12. doi: 10.1002/ijc.2910160502.

Abstract

Cell-mediated immunity (CMI) and tumor rejection were studied in the Friend virus leukemia system of C57Bl/6 mice. Mice were immunized with Friend leukemia virus (FLV) or X-irradiated FBL-3 leukemic cells and studied temporally for the development of CMI reactivity by assays of 51Cr release lymphocyte cytotoxicity, lymphocyte transformation, migration inhibition, Winn tumor cell neutralization and transplantation rejection. High levels of specific lymphocyte cytotoxicity were observed by day 7 f0llowing FLV infection; this reactivity reached a peak between 17 and 21 days, and returned to background levels by day 36. Further, positive Winn assays were obtained with spleen cells from mice immunized with FLV at times when the mice resisted live FBL-3 tumor challenge. Positive lymphocyte transformation was obtained with spleen cells from mice immunized with FLV or FBL-3, but not with cells from normal mice or mice immune to a syngeneic methycholanthrene-induced tumor, when cultured with papain-soluble FBL-3 or RBL-5 tumor-cell extracts or mitomycin-C (MMC)-treated FBL-3 or RBL-5 cells. Positive reactivity in the lymphocyte transformation assay occurred after reactivity had peaked in the lymphocyte cytotoxicity test. Similar positive macrophage migration inhibition patterns were also obtained with peritoneal exudate cells (PEC) from FLV-immunized mice using papain-solubilized tumor-associated antigen (TAA) from FBL-3 cells. These data suggest that sequential development and modulation of CMI reactivity occurs as observed in different assays following immunization in this system.

摘要

在C57Bl/6小鼠的弗氏病毒白血病系统中研究了细胞介导免疫(CMI)和肿瘤排斥反应。用弗氏白血病病毒(FLV)或经X射线照射的FBL-3白血病细胞对小鼠进行免疫,并通过51Cr释放淋巴细胞细胞毒性、淋巴细胞转化、迁移抑制、温氏肿瘤细胞中和及移植排斥试验,对CMI反应性的发展进行了时间上的研究。在FLV感染后第7天观察到高水平的特异性淋巴细胞细胞毒性;这种反应性在17至21天之间达到峰值,并在第36天恢复到背景水平。此外,在用FLV免疫的小鼠的脾细胞进行温氏试验时,当小鼠抵抗活的FBL-3肿瘤攻击时,获得了阳性结果。用FLV或FBL-3免疫的小鼠的脾细胞进行淋巴细胞转化试验呈阳性,但用正常小鼠或对同基因甲基胆蒽诱导肿瘤免疫的小鼠的细胞,与木瓜蛋白酶可溶性FBL-3或RBL-5肿瘤细胞提取物或丝裂霉素-C(MMC)处理的FBL-3或RBL-5细胞培养时则呈阴性。淋巴细胞转化试验中的阳性反应在淋巴细胞细胞毒性试验中的反应达到峰值后出现。用来自FLV免疫小鼠的腹腔渗出细胞(PEC),使用来自FBL-3细胞的木瓜蛋白酶可溶性肿瘤相关抗原(TAA),也获得了类似的阳性巨噬细胞迁移抑制模式。这些数据表明,在该系统中免疫后,如在不同试验中所观察到的,CMI反应性会发生顺序性发展和调节。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验